Medicus Pharma (NASDAQ:MDCX) Stock Price Down 4.6% – Should You Sell?

Medicus Pharma Ltd (NASDAQ:MDCX) traded down 4.6% on Tuesday . The company traded as low as $0.99 and last traded at $1.03. 1,663,053 shares were traded during trading, an increase of 467% from the average session volume of 293,178 shares. The stock had previously closed at $1.08.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. D. Boral Capital restated a “buy” rating and set a $27.00 price target on shares of Medicus Pharma in a research note on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Medicus Pharma in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $23.50.

Medicus Pharma Price Performance

The company has a market cap of $26.32 million, a PE ratio of -0.48 and a beta of -1.17. The stock’s 50-day moving average is $1.51 and its 200 day moving average is $2.01.

Medicus Pharma (NASDAQ:MDCX) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.27). On average, analysts expect that Medicus Pharma Ltd will post -1.14 EPS for the current year.

Institutional Investors Weigh In On Medicus Pharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Yorkville Advisors Global LP purchased a new stake in shares of Medicus Pharma during the third quarter valued at $532,000. Private Advisor Group LLC grew its stake in Medicus Pharma by 3.8% during the 3rd quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after purchasing an additional 5,500 shares during the last quarter. May Hill Capital LLC increased its holdings in shares of Medicus Pharma by 100.0% in the fourth quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock valued at $55,000 after purchasing an additional 17,811 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Medicus Pharma in the 3rd quarter worth approximately $59,000. Finally, Brave Asset Management Inc. purchased a new position in Medicus Pharma during the 3rd quarter worth approximately $46,000.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.